Benzinga | Apr 22, 2021 09:04AM EDT

Hoth Therapeutics Says First In Human Clinical Trial For Treatment Of Atopic Dermatitis With BioLexa Is Underway

Hoth Therapeutics, Inc. (NASDAQ:HOTH), a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs, is pleased to announce the start of its First in Human clinical trial investigating topical BioLexa for the treatment of mild to moderate atopic dermatitis, also known as eczema.